Sumitomo Mitsui Trust Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,407	Closed	-$318K	–	1075
2025 Q1	$318K	Buy	+2,407	New	+$300K	﹤0.01%	980

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sumitomo Mitsui Trust Group's ITCI Position: Q2 2025 in Review

Sumitomo Mitsui Trust Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,407 shares — an estimated $318K sold.

Sumitomo Mitsui Trust Group first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $318K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Sumitomo Mitsui Trust Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Sumitomo Mitsui Trust Group sold 2,407 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $318K.
Sumitomo Mitsui Trust Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Sumitomo Mitsui Trust Group's Intra-Cellular Therapies Inc. position peaked at $318K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2025, filed 31 Jul 2025.